



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 23, 2018

PTAS

STERNE, KESSLER, GOLDSTEIN & FOX
P.L.L.C
1100 NEW YORK AVENUE, NW
WASHINGTON, DC 20005

504925682

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 05/22/2018

REEL/FRAME: 045873/0015
NUMBER OF PAGES: 20

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 3986.0090003/EKS/CLD/M-S

ASSIGNOR:

KAPLAN, CHARLES

DOC DATE: 05/03/2018

ASSIGNOR:

HOUSER, DERRICK

DOC DATE: 05/18/2018

ASSIGNOR:

BORGES, LUIS

DOC DATE: 05/03/2018

ASSIGNOR:

BRATTICH, GLORIA

DOC DATE: 05/03/2018

ASSIGNOR:

BELLOVIN, DAVID

DOC DATE: 05/07/2018

ASSIGNOR:

KEMP, FELICIA

DOC DATE: 05/03/2018

ASSIGNOR:

GHODDUSI, MAJID

DOC DATE: 05/03/2018

ASSIGNOR:
MILLER, KATHY

DOC DATE: 05/18/2018

ASSIGNEE:
FIVE PRIME THERAPEUTICS, INC.
111 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CALIFORNIA
94080

APPLICATION NUMBER: 62550173 FILING DATE: 08/25/2017
PATENT NUMBER: ISSUE DATE:
TITLE: B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

APPLICATION NUMBER: 62579774 FILING DATE: 10/31/2017
PATENT NUMBER: ISSUE DATE:
TITLE: B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

APPLICATION NUMBER: 62607810 FILING DATE: 12/19/2017
PATENT NUMBER: ISSUE DATE:
TITLE: B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

APPLICATION NUMBER: 62656789 FILING DATE: 04/12/2018
PATENT NUMBER: ISSUE DATE:
TITLE: B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)*Electronic Patent Assignment System***Confirmation Receipt**

Your assignment has been received by the USPTO.
The coversheet of the assignment is displayed below:

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1

Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT																		
NATURE OF CONVEYANCE:	ASSIGNMENT																		
CONVEYING PARTY DATA																			
<table border="1"><thead><tr><th>Name</th><th>Execution Date</th></tr></thead><tbody><tr><td>CHARLES KAPLAN</td><td>05/03/2018</td></tr><tr><td>DERRICK HOUSER</td><td>05/18/2018</td></tr><tr><td>LUIS BORGES</td><td>05/03/2018</td></tr><tr><td>GLORIA BRATTICH</td><td>05/03/2018</td></tr><tr><td>DAVID BELLOVIN</td><td>05/07/2018</td></tr><tr><td>FELICIA KEMP</td><td>05/03/2018</td></tr><tr><td>MAJID GHODDUSI</td><td>05/03/2018</td></tr><tr><td>KATHY MILLER</td><td>05/18/2018</td></tr></tbody></table>		Name	Execution Date	CHARLES KAPLAN	05/03/2018	DERRICK HOUSER	05/18/2018	LUIS BORGES	05/03/2018	GLORIA BRATTICH	05/03/2018	DAVID BELLOVIN	05/07/2018	FELICIA KEMP	05/03/2018	MAJID GHODDUSI	05/03/2018	KATHY MILLER	05/18/2018
Name	Execution Date																		
CHARLES KAPLAN	05/03/2018																		
DERRICK HOUSER	05/18/2018																		
LUIS BORGES	05/03/2018																		
GLORIA BRATTICH	05/03/2018																		
DAVID BELLOVIN	05/07/2018																		
FELICIA KEMP	05/03/2018																		
MAJID GHODDUSI	05/03/2018																		
KATHY MILLER	05/18/2018																		
RECEIVING PARTY DATA																			
<table border="1"><tr><td>Name:</td><td>FIVE PRIME THERAPEUTICS, INC.</td></tr><tr><td>Street Address:</td><td>111 OYSTER POINT BLVD.</td></tr><tr><td>City:</td><td>SOUTH SAN FRANCISCO</td></tr><tr><td>State/Country:</td><td>CALIFORNIA</td></tr><tr><td>Postal Code:</td><td>94080</td></tr></table>		Name:	FIVE PRIME THERAPEUTICS, INC.	Street Address:	111 OYSTER POINT BLVD.	City:	SOUTH SAN FRANCISCO	State/Country:	CALIFORNIA	Postal Code:	94080								
Name:	FIVE PRIME THERAPEUTICS, INC.																		
Street Address:	111 OYSTER POINT BLVD.																		
City:	SOUTH SAN FRANCISCO																		
State/Country:	CALIFORNIA																		
Postal Code:	94080																		
PROPERTY NUMBERS Total: 4																			

Property Type	Number
Application Number:	62550173
Application Number:	62579774
Application Number:	62607810
Application Number:	62656789

CORRESPONDENCE DATA

Fax Number: (202)371-2540
Phone: 2023712600
Email: msmith@sternekessler.com, deniseb@sternekessler.com
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.
Correspondent Name: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C
Address Line 1: 1100 NEW YORK AVENUE, NW
Address Line 4: WASHINGTON, D.C. 20005

ATTORNEY DOCKET
NUMBER:

3986.0090003/EKS/CLD/M-S

NAME OF SUBMITTER:

CYNTHIA L. DERENZO

Signature:

/Cynthia L. DeRenzo #60,789/

Date:

05/22/2018

Total Attachments: 18

source=FIVE_PRIME_ASGN#page1.tif
source=FIVE_PRIME_ASGN#page2.tif
source=FIVE_PRIME_ASGN#page3.tif
source=FIVE_PRIME_ASGN#page4.tif
source=FIVE_PRIME_ASGN#page5.tif
source=FIVE_PRIME_ASGN#page6.tif
source=FIVE_PRIME_ASGN#page7.tif
source=FIVE_PRIME_ASGN#page8.tif
source=FIVE_PRIME_ASGN#page9.tif
source=FIVE_PRIME_ASGN#page10.tif
source=FIVE_PRIME_ASGN#page11.tif
source=FIVE_PRIME_ASGN#page12.tif
source=FIVE_PRIME_ASGN#page13.tif
source=FIVE_PRIME_ASGN#page14.tif
source=FIVE_PRIME_ASGN#page15.tif
source=FIVE_PRIME_ASGN#page16.tif
source=FIVE_PRIME_ASGN#page17.tif
source=FIVE_PRIME_ASGN#page18.tif

RECEIPT INFORMATION

EPAS ID:	PAT4972428
Receipt Date:	05/22/2018

[Return to home page](#)

[| .HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)
**Electronic Patent Assignment System**

Patent Assignment Recordation Form

 Navigation: [Guidelines](#) - [Conveyance Type](#) - [Correspondence](#) - [Conveyor](#) - [Receiver](#) - [Property](#) - [Attachments](#) - [Sign](#) - [Validate](#)

 EPAS v.1.11
 PTO-1595 (Rev. 06/12)
 OMB No. 0651-0027 (Exp.
 04/30/2018)
Validate

All data entered on the previous screens are displayed below. Check the data carefully. If you find any errors, go back to the appropriate screen and correct. Otherwise, select the Submit button to proceed.

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1

Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT																		
NATURE OF CONVEYANCE:	ASSIGNMENT																		
CONVEYING PARTY DATA																			
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 60%;">Name</th> <th style="width: 40%;">Execution Date</th> </tr> </thead> <tbody> <tr><td>CHARLES KAPLAN</td><td>05/03/2018</td></tr> <tr><td>DERRICK HOUSER</td><td>05/18/2018</td></tr> <tr><td>LUIS BORGES</td><td>05/03/2018</td></tr> <tr><td>GLORIA BRATTICH</td><td>05/03/2018</td></tr> <tr><td>DAVID BELLOVIN</td><td>05/07/2018</td></tr> <tr><td>FELICIA KEMP</td><td>05/03/2018</td></tr> <tr><td>MAJID GHODDUSI</td><td>05/03/2018</td></tr> <tr><td>KATHY MILLER</td><td>05/18/2018</td></tr> </tbody> </table>		Name	Execution Date	CHARLES KAPLAN	05/03/2018	DERRICK HOUSER	05/18/2018	LUIS BORGES	05/03/2018	GLORIA BRATTICH	05/03/2018	DAVID BELLOVIN	05/07/2018	FELICIA KEMP	05/03/2018	MAJID GHODDUSI	05/03/2018	KATHY MILLER	05/18/2018
Name	Execution Date																		
CHARLES KAPLAN	05/03/2018																		
DERRICK HOUSER	05/18/2018																		
LUIS BORGES	05/03/2018																		
GLORIA BRATTICH	05/03/2018																		
DAVID BELLOVIN	05/07/2018																		
FELICIA KEMP	05/03/2018																		
MAJID GHODDUSI	05/03/2018																		
KATHY MILLER	05/18/2018																		
RECEIVING PARTY DATA																			
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%;">Name:</td> <td>FIVE PRIME THERAPEUTICS, INC.</td> </tr> <tr> <td>Street Address:</td> <td>111 OYSTER POINT BLVD.</td> </tr> <tr> <td>City:</td> <td>SOUTH SAN FRANCISCO</td> </tr> <tr> <td>State/Country:</td> <td>CALIFORNIA</td> </tr> <tr> <td>Postal Code:</td> <td>94080</td> </tr> </table>		Name:	FIVE PRIME THERAPEUTICS, INC.	Street Address:	111 OYSTER POINT BLVD.	City:	SOUTH SAN FRANCISCO	State/Country:	CALIFORNIA	Postal Code:	94080								
Name:	FIVE PRIME THERAPEUTICS, INC.																		
Street Address:	111 OYSTER POINT BLVD.																		
City:	SOUTH SAN FRANCISCO																		
State/Country:	CALIFORNIA																		
Postal Code:	94080																		
PROPERTY NUMBERS Total: 4																			

Property Type	Number
Application Number:	62550173
Application Number:	62579774
Application Number:	62607810
Application Number:	62656789

CORRESPONDENCE DATA	
Fax Number:	(202)371-2540
Phone:	2023712600
Email:	msmith@sternekessler.com, deniseb@sternekessler.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C
Address Line 1:	1100 NEW YORK AVENUE, NW
Address Line 4:	WASHINGTON, D.C. 20005

NAME OF SUBMITTER:	CYNTHIA L. DERENZO
Signature:	/Cynthia L. DeRenzo #60,789/
Date:	05/22/2018

Total Attachments: 18 source=FIVE_PRIME_ASGN#page1.tif source=FIVE_PRIME_ASGN#page2.tif source=FIVE_PRIME_ASGN#page3.tif source=FIVE_PRIME_ASGN#page4.tif source=FIVE_PRIME_ASGN#page5.tif source=FIVE_PRIME_ASGN#page6.tif source=FIVE_PRIME_ASGN#page7.tif source=FIVE_PRIME_ASGN#page8.tif source=FIVE_PRIME_ASGN#page9.tif source=FIVE_PRIME_ASGN#page10.tif source=FIVE_PRIME_ASGN#page11.tif source=FIVE_PRIME_ASGN#page12.tif source=FIVE_PRIME_ASGN#page13.tif source=FIVE_PRIME_ASGN#page14.tif source=FIVE_PRIME_ASGN#page15.tif source=FIVE_PRIME_ASGN#page16.tif source=FIVE_PRIME_ASGN#page17.tif source=FIVE_PRIME_ASGN#page18.tif

Attorney Docket Number:

3986.0090003/EKS/CLD/M-S

This U.S. GOVERNMENT System is for recording documents with the U.S. Patent and Trademark Office.

There is no right to privacy in this system. Use of this system constitutes consent to have activities in association with the submission for recordation monitored, recorded, read, copied or captured by authorized personnel. Unauthorized use of this service, which includes providing false or spurious information such as false or improper assignment documents or security agreements, is a misrepresentation to the federal government. Unauthorized use of this system is prohibited and subject to criminal and civil penalties, including all penalties applicable to willful unauthorized access. See 37 CFR 1.4, 11.18 and 18 U.S.C. 1001.

The USPTO reserves the right, at its complete discretion, to change the terms, conditions, and use at any time by posting revised terms, conditions, and use restrictions for this system. It is the user's responsibility to check periodically for any changes USPTO may make to these terms, conditions, and use restrictions. Continued use of this system following the posting of changes to these terms, conditions, and use restrictions means you accept the changes.

☒ By checking this box, you acknowledge your consent to the above statement.

Your IP address: 208.184.134.166

Submit

Back

Cancel

Advanced Operations

Save form for future access, or prepare a template

[.HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)

05/22/2018 02:51 PM EDT

ASSIGNMENT

WHEREAS we, the below named inventors (hereinafter referred to as Assignors) have made an invention entitled:

B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

for which we executed United States Provisional Application Nos. 62/550,173 filed on August 25, 2017, 62/579,774 filed on October 31, 2017, 62/607,810 filed on December 19, 2017, and 62/656,789 filed on April 12, 2018; and

WHEREAS, Five Prime Therapeutics, Inc., a corporation whose post office address is 111 Oyster Point Blvd, South San Francisco, California 94080 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to this provisional patent application and any subsequent application filed in any jurisdiction throughout the world claiming priority to this provisional application, and in and to any Letters Patent to be issued upon this provisional application or on an application claiming priority to this provisional application in any jurisdiction throughout the world;


NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, we, as Assignors, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, and this provisional application, and to all applications in any worldwide jurisdiction that claim priority to this provisional application, including all divisions and continuations thereof, and all Letters Patent in any worldwide jurisdiction that may be granted thereon, including all reissues, reexaminations, renewals, extensions, and supplemental patent certificates thereof. We have also sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns all rights to claim priority in any worldwide jurisdiction on the basis of the above provisional application. We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE HEREBY covenant that we have the full right to convey the interest assigned by this Assignment, and we have not executed and will not execute any agreement in conflict with this Assignment;


AND, WE HEREBY further covenant and agree that we will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country.

AND, WE HEREBY authorize and request the attorneys given power of attorney in this application.

IN TESTIMONY WHEREOF, we have hereunto set our hands.



Charles Kaplan



DATE

Derrick Houser

DATE

SOLE/JOINT INVENTION
(Worldwide Rights)
Client Reference No. P1052-PR1, PR2, PR3, PR4-US

_____ Luis Borges	_____ DATE
_____ Gloria Brattich	_____ DATE
_____ David Bellovin	_____ DATE
_____ Felicia Kemp	_____ DATE
_____ Majid Ghoddusi	_____ DATE
_____ Kathy Miller	_____ DATE

IN TESTIMONY WHEREOF, ASSIGNEE acknowledges this assignment and hereunto signed ASSIGNEE'S name to this Assignment on the date indicated below.

FIVE PRIME THERAPEUTICS, INC.

By: _____

Date: _____

Name: _____

Title: _____

ASSIGNMENT

WHEREAS we, the below named inventors (hereinafter referred to as Assignors) have made an invention entitled:

B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

for which we executed United States Provisional Application Nos. 62/550,173 filed on August 25, 2017, 62/579,774 filed on October 31, 2017, 62/607,810 filed on December 19, 2017, and 62/656,789 filed on April 12, 2018; and

WHEREAS, Five Prime Therapeutics, Inc., a corporation whose post office address is 111 Oyster Point Blvd, South San Francisco, California 94080 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to this provisional patent application and any subsequent application filed in any jurisdiction throughout the world claiming priority to this provisional application, and in and to any Letters Patent to be issued upon this provisional application or on an application claiming priority to this provisional application in any jurisdiction throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, we, as Assignors, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, and this provisional application, and to all applications in any worldwide jurisdiction that claim priority to this provisional application, including all divisions and continuations thereof, and all Letters Patent in any worldwide jurisdiction that may be granted thereon, including all reissues, reexaminations, renewals, extensions, and supplemental patent certificates thereof. We have also sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns all rights to claim priority in any worldwide jurisdiction on the basis of the above provisional application. We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE HEREBY covenant that we have the full right to convey the interest assigned by this Assignment, and we have not executed and will not execute any agreement in conflict with this Assignment;

AND, WE HEREBY further covenant and agree that we will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country.

AND, WE HEREBY authorize and request the attorneys given power of attorney in this application.

IN TESTIMONY WHEREOF, we have hereunto set our hands.

_____ Charles Kaplan	_____ DATE
 Derrick Houser	05.18.18 _____ DATE

SOLE/JOINT INVENTION
(Worldwide Rights)
Client Reference No. P1052-PR1, PR2, PR3, PR4-US

_____ Luis Borges	_____ DATE
_____ Gloria Brattich	_____ DATE
_____ David Bellovin	_____ DATE
_____ Felicia Kemp	_____ DATE
_____ Majid Ghoddusi	_____ DATE
_____ Kathy Miller	_____ DATE

IN TESTIMONY WHEREOF, ASSIGNEE acknowledges this assignment and hereunto signed ASSIGNEE'S name to this Assignment on the date indicated below.

FIVE PRIME THERAPEUTICS, INC.

By: _____

Date: _____

Name: _____

Title: _____

ASSIGNMENT

WHEREAS we, the below named inventors (hereinafter referred to as Assignors) have made an invention entitled:

B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

for which we executed United States Provisional Application Nos. 62/550,173 filed on August 25, 2017, 62/579,774 filed on October 31, 2017, 62/607,810 filed on December 19, 2017, and 62/656,789 filed on April 12, 2018; and

WHEREAS, Five Prime Therapeutics, Inc., a corporation whose post office address is 111 Oyster Point Blvd, South San Francisco, California 94080 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to this provisional patent application and any subsequent application filed in any jurisdiction throughout the world claiming priority to this provisional application, and in and to any Letters Patent to be issued upon this provisional application or on an application claiming priority to this provisional application in any jurisdiction throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, we, as Assignors, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, and this provisional application, and to all applications in any worldwide jurisdiction that claim priority to this provisional application, including all divisions and continuations thereof, and all Letters Patent in any worldwide jurisdiction that may be granted thereon, including all reissues, reexaminations, renewals, extensions, and supplemental patent certificates thereof. We have also sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns all rights to claim priority in any worldwide jurisdiction on the basis of the above provisional application. We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE HEREBY covenant that we have the full right to convey the interest assigned by this Assignment, and we have not executed and will not execute any agreement in conflict with this Assignment;

AND, WE HEREBY further covenant and agree that we will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country.

AND, WE HEREBY authorize and request the attorneys given power of attorney in this application.

IN TESTIMONY WHEREOF, we have hereunto set our hands.

Charles Kaplan

DATE

Derrick Houser

DATE

SOLE/JOINT INVENTION
(Worldwide Rights)
Client Reference No. P1052-PR1, PR2, PR3, PR4-US

Luis Borges
Luis Borges

5/3/2018
DATE

Gloria Brattich
Gloria Brattich

DATE

David Bellovin
David Bellovin

DATE

Felicia Kemp
Felicia Kemp

DATE

Majid Ghoddusi
Majid Ghoddusi

DATE

Kathy Miller
Kathy Miller

DATE

IN TESTIMONY WHEREOF, ASSIGNEE acknowledges this assignment and hereunto signed ASSIGNEE'S
name to this Assignment on the date indicated below.

FIVE PRIME THERAPEUTICS, INC.

By: _____

Date: _____

Name: _____

Title: _____

ASSIGNMENT

WHEREAS we, the below named inventors (hereinafter referred to as Assignors) have made an invention entitled:

B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

for which we executed United States Provisional Application Nos. 62/550,173 filed on August 25, 2017, 62/579,774 filed on October 31, 2017, 62/607,810 filed on December 19, 2017, and 62/656,789 filed on April 12, 2018; and

WHEREAS, Five Prime Therapeutics, Inc., a corporation whose post office address is 111 Oyster Point Blvd, South San Francisco, California 94080 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to this provisional patent application and any subsequent application filed in any jurisdiction throughout the world claiming priority to this provisional application, and in and to any Letters Patent to be issued upon this provisional application or on an application claiming priority to this provisional application in any jurisdiction throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, we, as Assignors, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, and this provisional application, and to all applications in any worldwide jurisdiction that claim priority to this provisional application, including all divisions and continuations thereof, and all Letters Patent in any worldwide jurisdiction that may be granted thereon, including all reissues, reexaminations, renewals, extensions, and supplemental patent certificates thereof. We have also sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns all rights to claim priority in any worldwide jurisdiction on the basis of the above provisional application. We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE HEREBY covenant that we have the full right to convey the interest assigned by this Assignment, and we have not executed and will not execute any agreement in conflict with this Assignment;

AND, WE HEREBY further covenant and agree that we will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country.

AND, WE HEREBY authorize and request the attorneys given power of attorney in this application.

IN TESTIMONY WHEREOF, we have hereunto set our hands.

Charles Kaplan

DATE

Derrick Houser

DATE

SOLE/JOINT INVENTION
(Worldwide Rights)
Client Reference No. P1052-PR1, PR2, PR3, PR4-US

Luis Borges

DATE

Gloria Brattich

Gloria Brattich

2018-05-03

DATE

David Bellovin

DATE

Felicia Kemp

DATE

Majid Ghoddusi

DATE

Kathy Miller

DATE

IN TESTIMONY WHEREOF, ASSIGNEE acknowledges this assignment and hereunto signed ASSIGNEE'S name to this Assignment on the date indicated below.

FIVE PRIME THERAPEUTICS, INC.

By: _____

Date: _____

Name: _____

Title: _____

ASSIGNMENT

WHEREAS we, the below named inventors (hereinafter referred to as Assignors) have made an invention entitled:

B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

for which we executed United States Provisional Application Nos. 62/550,173 filed on August 25, 2017, 62/579,774 filed on October 31, 2017, 62/607,810 filed on December 19, 2017, and 62/656,789 filed on April 12, 2018; and

WHEREAS, Five Prime Therapeutics, Inc., a corporation whose post office address is 111 Oyster Point Blvd, South San Francisco, California 94080 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to this provisional patent application and any subsequent application filed in any jurisdiction throughout the world claiming priority to this provisional application, and in and to any Letters Patent to be issued upon this provisional application or on an application claiming priority to this provisional application in any jurisdiction throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, we, as Assignors, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, and this provisional application, and to all applications in any worldwide jurisdiction that claim priority to this provisional application, including all divisions and continuations thereof, and all Letters Patent in any worldwide jurisdiction that may be granted thereon, including all reissues, reexaminations, renewals, extensions, and supplemental patent certificates thereof. We have also sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns all rights to claim priority in any worldwide jurisdiction on the basis of the above provisional application. We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE HEREBY covenant that we have the full right to convey the interest assigned by this Assignment, and we have not executed and will not execute any agreement in conflict with this Assignment;

AND, WE HEREBY further covenant and agree that we will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country.

AND, WE HEREBY authorize and request the attorneys given power of attorney in this application.

IN TESTIMONY WHEREOF, we have hereunto set our hands.

Charles Kaplan

DATE

Derrick Houser

DATE

SOLE/JOINT INVENTION
(Worldwide Rights)
Client Reference No. P1052-PR1, PR2, PR3, PR4-US

Luis Borges


DATE

Gloria Brattich

DATE



David Bellovin



DATE

Felicia Kemp

DATE

Majid Ghoddusi

DATE

Kathy Miller

DATE

IN TESTIMONY WHEREOF, ASSIGNEE acknowledges this assignment and hereunto signed ASSIGNEE'S name to this Assignment on the date indicated below.

FIVE PRIME THERAPEUTICS, INC.

By: _____

Date: _____

Name: _____

Title: _____

ASSIGNMENT

WHEREAS we, the below named inventors (hereinafter referred to as Assignors) have made an invention entitled:

B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

for which we executed United States Provisional Application Nos. 62/550,173 filed on August 25, 2017, 62/579,774 filed on October 31, 2017, 62/607,810 filed on December 19, 2017, and 62/656,789 filed on April 12, 2018; and

WHEREAS, Five Prime Therapeutics, Inc., a corporation whose post office address is 111 Oyster Point Blvd, South San Francisco, California 94080 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to this provisional patent application and any subsequent application filed in any jurisdiction throughout the world claiming priority to this provisional application, and in and to any Letters Patent to be issued upon this provisional application or on an application claiming priority to this provisional application in any jurisdiction throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, we, as Assignors, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, and this provisional application, and to all applications in any worldwide jurisdiction that claim priority to this provisional application, including all divisions and continuations thereof, and all Letters Patent in any worldwide jurisdiction that may be granted thereon, including all reissues, reexaminations, renewals, extensions, and supplemental patent certificates thereof. We have also sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns all rights to claim priority in any worldwide jurisdiction on the basis of the above provisional application. We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE HEREBY covenant that we have the full right to convey the interest assigned by this Assignment, and we have not executed and will not execute any agreement in conflict with this Assignment;

AND, WE HEREBY further covenant and agree that we will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country.

AND, WE HEREBY authorize and request the attorneys given power of attorney in this application.

IN TESTIMONY WHEREOF, we have hereunto set our hands.

Charles Kaplan

DATE

Derrick Houser

DATE

SOLE/JOINT INVENTION
(Worldwide Rights)
Client Reference No. P1052-PR1, PR2, PR3, PR4-US

Luis Borges


DATE

Gloria Brattich

DATE

David Bellovin

DATE



Felicia Kemp

05 03 2018

DATE

Majid Ghoddusi

DATE

Kathy Miller

DATE

IN TESTIMONY WHEREOF, ASSIGNEE acknowledges this assignment and hereunto signed ASSIGNEE'S
name to this Assignment on the date indicated below.

FIVE PRIME THERAPEUTICS, INC.

By: _____

Date: _____

Name: _____

Title: _____

ASSIGNMENT

WHEREAS we, the below named inventors (hereinafter referred to as Assignors) have made an invention entitled:

B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

for which we executed United States Provisional Application Nos. 62/550,173 filed on August 25, 2017, 62/579,774 filed on October 31, 2017, 62/607,810 filed on December 19, 2017, and 62/656,789 filed on April 12, 2018; and

WHEREAS, Five Prime Therapeutics, Inc., a corporation whose post office address is 111 Oyster Point Blvd, South San Francisco, California 94080 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to this provisional patent application and any subsequent application filed in any jurisdiction throughout the world claiming priority to this provisional application, and in and to any Letters Patent to be issued upon this provisional application or on an application claiming priority to this provisional application in any jurisdiction throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, we, as Assignors, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, and this provisional application, and to all applications in any worldwide jurisdiction that claim priority to this provisional application, including all divisions and continuations thereof, and all Letters Patent in any worldwide jurisdiction that may be granted thereon, including all reissues, reexaminations, renewals, extensions, and supplemental patent certificates thereof. We have also sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns all rights to claim priority in any worldwide jurisdiction on the basis of the above provisional application. We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE HEREBY covenant that we have the full right to convey the interest assigned by this Assignment, and we have not executed and will not execute any agreement in conflict with this Assignment;

AND, WE HEREBY further covenant and agree that we will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country.

AND, WE HEREBY authorize and request the attorneys given power of attorney in this application.

IN TESTIMONY WHEREOF, we have hereunto set our hands.


Charles Kaplan

DATE

Derrick Houser

DATE

SOLE/JOINT INVENTION
(Worldwide Rights)
Client Reference No. P1052-PR1, PR2, PR3, PR4-US

_____ Luis Borges	_____ DATE
_____ Gloria Brattlich	_____ DATE
_____ David Bellovin	_____ DATE
_____ Felicia Kemp	_____ DATE
_____  Majid Ghoddusi	_____ 5/3/2018 DATE
_____ Kathy Miller	_____ DATE

IN TESTIMONY WHEREOF, ASSIGNEE acknowledges this assignment and hereunto signed ASSIGNEE'S name to this Assignment on the date indicated below.

FIVE PRIME THERAPEUTICS, INC.

By: _____

Date: _____

Name: _____

Title: _____

SOLE/JOINT INVENTION
(Worldwide Rights)

Client Reference No. P1052-PR1, PR2, PR3, PR4-US

ASSIGNMENT

WHEREAS we, the below named inventors (hereinafter referred to as Assignors) have made an invention entitled:

B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

for which we executed United States Provisional Application Nos. 62/550,173 filed on August 25, 2017, 62/579,774 filed on October 31, 2017, 62/607,810 filed on December 19, 2017, and 62/656,789 filed on April 12, 2018; and

WHEREAS, Five Prime Therapeutics, Inc., a corporation whose post office address is 111 Oyster Point Blvd, South San Francisco, California 94080 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to this provisional patent application and any subsequent application filed in any jurisdiction throughout the world claiming priority to this provisional application, and in and to any Letters Patent to be issued upon this provisional application or on an application claiming priority to this provisional application in any jurisdiction throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, we, as Assignors, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, and this provisional application, and to all applications in any worldwide jurisdiction that claim priority to this provisional application, including all divisions and continuations thereof, and all Letters Patent in any worldwide jurisdiction that may be granted thereon, including all reissues, reexaminations, renewals, extensions, and supplemental patent certificates thereof. We have also sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns all rights to claim priority in any worldwide jurisdiction on the basis of the above provisional application. We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE HEREBY covenant that we have the full right to convey the interest assigned by this Assignment, and we have not executed and will not execute any agreement in conflict with this Assignment;

AND, WE HEREBY further covenant and agree that we will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country.

AND, WE HEREBY authorize and request the attorneys given power of attorney in this application.

IN TESTIMONY WHEREOF, we have hereunto set our hands.

Charles Kaplan

DATE

Derrick Houser

DATE

SOLE/JOINT INVENTION
(Worldwide Rights)
Client Reference No. P1052-PR1, PR2, PR3, PR4-US

Luis Borges

DATE

Gloria Brattich

DATE

David Bellovin


DATE

Felicia Kemp

DATE

Majid Ghoddusi

DATE


Kathy Miller

18 May 2018
DATE

IN TESTIMONY WHEREOF, ASSIGNEE acknowledges this assignment and hereunto signed ASSIGNEE'S name to this Assignment on the date indicated below.

FIVE PRIME THERAPEUTICS, INC.

By: _____

Date: _____

Name: _____

Title: _____

SOLE/JOINT INVENTION

(Worldwide Rights)

Client Reference No. P1052-PR1, PR2, PR3, PR4-US

ASSIGNMENT

WHEREAS we, the below named inventors (hereinafter referred to as Assignors) have made an invention entitled:

B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

for which we executed United States Provisional Application Nos. 62/550,173 filed on August 25, 2017, 62/579,774 filed on October 31, 2017, 62/607,810 filed on December 19, 2017, and 62/656,789 filed on April 12, 2018; and

WHEREAS, Five Prime Therapeutics, Inc., a corporation whose post office address is 111 Oyster Point Blvd, South San Francisco, California 94080 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to this provisional patent application and any subsequent application filed in any jurisdiction throughout the world claiming priority to this provisional application, and in and to any Letters Patent to be issued upon this provisional application or on an application claiming priority to this provisional application in any jurisdiction throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, we, as Assignors, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, and this provisional application, and to all applications in any worldwide jurisdiction that claim priority to this provisional application, including all divisions and continuations thereof, and all Letters Patent in any worldwide jurisdiction that may be granted thereon, including all reissues, reexaminations, renewals, extensions, and supplemental patent certificates thereof. We have also sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns all rights to claim priority in any worldwide jurisdiction on the basis of the above provisional application. We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE HEREBY covenant that we have the full right to convey the interest assigned by this Assignment, and we have not executed and will not execute any agreement in conflict with this Assignment;

AND, WE HEREBY further covenant and agree that we will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country.

AND, WE HEREBY authorize and request the attorneys given power of attorney in this application.

IN TESTIMONY WHEREOF, we have hereunto set our hands.

Charles Kaplan

DATE

Derrick Houser

DATE

SOLE/JOINT INVENTION
(Worldwide Rights)
Client Reference No. P1052-PR1, PR2, PR3, PR4-US

Luis Borges

DATE

Gloria Brattich

DATE

David Bellovin

DATE

Felicia Kemp

DATE

Majid Ghoddusi


DATE

Kathy Miller

DATE

IN TESTIMONY WHEREOF, ASSIGNEE acknowledges this assignment and hereunto signed ASSIGNEE'S
name to this Assignment on the date indicated below.

FIVE PRIME THERAPEUTICS, INC.

By: 

Date: May 21, 2018

Name: Francis Sarena

Title: Chief Strategy Officer and Secretary



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 23, 2018

PTAS

STERNE, KESSLER, GOLDSTEIN & FOX
P.L.L.C
1100 NEW YORK AVENUE, NW
WASHINGTON, DC 20005

504925689

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 05/22/2018

REEL/FRAME: 045873/0051
NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 3986.0090003/EKS/CLD/M-S

ASSIGNOR:

NIELSON, NELS P.

DOC DATE: 05/04/2018

ASSIGNEE:

ADIMAB, LLC
7 LUCENT DRIVE
LEBANON, NEW HAMPSHIRE 03766

APPLICATION NUMBER: 62550173

FILING DATE: 08/25/2017

PATENT NUMBER:

ISSUE DATE:

TITLE: B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

APPLICATION NUMBER: 62579774

FILING DATE: 10/31/2017

PATENT NUMBER:

ISSUE DATE:

TITLE: B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

APPLICATION NUMBER: 62607810

FILING DATE: 12/19/2017

PATENT NUMBER:

ISSUE DATE:

TITLE: B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

APPLICATION NUMBER: 62656789

FILING DATE: 04/12/2018

PATENT NUMBER:

ISSUE DATE:

TITLE: B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

ASSIGNMENT RECORDATION BRANCH

PUBLIC RECORDS DIVISION



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)*Electronic Patent Assignment System***Confirmation Receipt**

Your assignment has been received by the USPTO.
The coversheet of the assignment is displayed below:

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NELS P. NIELSON	05/04/2018
RECEIVING PARTY DATA	
Name:	ADIMAB, LLC
Street Address:	7 LUCENT DRIVE
City:	LEBANON
State/Country:	NEW HAMPSHIRE
Postal Code:	03766
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	62550173
Application Number:	62579774
Application Number:	62607810
Application Number:	62656789

CORRESPONDENCE DATA

Fax Number: (202)371-2540

Phone: 2023712600

Email: msmith@sternekessler.com, deniseb@sternekessler.com

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Correspondent Name: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C

Address Line 1: 1100 NEW YORK AVENUE, NW

Address Line 4: WASHINGTON, D.C. 20005

ATTORNEY DOCKET
NUMBER:

3986.0090003/EKS/CLD/M-S

NAME OF SUBMITTER:

CYNTHIA L. DERENZO

Signature:

/Cynthia L. DeRenzo #60,789/

Date:

05/22/2018

Total Attachments: 2

source=ADIMAB_ASGN#page1.tif

source=ADIMAB_ASGN#page2.tif

RECEIPT INFORMATION

EPAS ID: PAT4972435

Receipt Date: 05/22/2018

[Return to home page](#)[| .HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)
**Electronic Patent Assignment System**

Patent Assignment Recordation Form

Navigation: [Guidelines](#) - [Conveyance Type](#) - [Correspondence](#) - [Conveyor](#) - [Receiver](#) - [Property](#) -[Attachments](#) - [Sign](#) - [Validate](#)
 EPAS v.1.11
 PTO-1595 (Rev. 06/12)
 OMB No. 0651-0027 (Exp.
 04/30/2018)
Validate

All data entered on the previous screens are displayed below. Check the data carefully. If you find any errors, go back to the appropriate screen and correct. Otherwise, select the Submit button to proceed.

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1

Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NELS P. NIELSON	05/04/2018
RECEIVING PARTY DATA	
Name:	ADIMAB, LLC
Street Address:	7 LUCENT DRIVE
City:	LEBANON
State/Country:	NEW HAMPSHIRE
Postal Code:	03766
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	62550173
Application Number:	62579774
Application Number:	62607810
Application Number:	62656789

CORRESPONDENCE DATA

Fax Number: (202)371-2540
 Phone: 2023712600
 Email: msmith@sternekessler.com, deniseb@sternekessler.com
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.
 Correspondent Name: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C
 Address Line 1: 1100 NEW YORK AVENUE, NW
 Address Line 4: WASHINGTON, D.C. 20005

NAME OF SUBMITTER:	CYNTHIA L. DERENZO
Signature:	/Cynthia L. DeRenzo #60,789/
Date:	05/22/2018
Total Attachments: 2 source=ADIMAB_ASGN#page1.tif source=ADIMAB_ASGN#page2.tif	

Attorney Docket Number:

3986.0090003/EKS/CLD/M-S

This U.S. GOVERNMENT System is for recording documents with the U.S. Patent and Trademark Office.

There is no right to privacy in this system. Use of this system constitutes consent to have activities in association with the submission for recordation monitored, recorded, read, copied or captured by authorized personnel. Unauthorized use of this service, which includes providing false or spurious information such as false or improper assignment documents or security agreements, is a misrepresentation to the federal government. Unauthorized use of this system is prohibited and subject to criminal and civil penalties, including all penalties applicable to willful unauthorized access. See 37 CFR 1.4, 11.18 and 18 U.S.C. 1001.

The USPTO reserves the right, at its complete discretion, to change the terms, conditions, and use at any time by posting revised terms, conditions, and use restrictions for this system. It is the user's responsibility to check periodically for any changes USPTO may make to these terms, conditions, and use restrictions. Continued use of this system following the posting of changes to these terms, conditions, and use restrictions means you accept the changes.

☒ By checking this box, you acknowledge your consent to the above statement.

Your IP address: 208.184.134.166

Submit

Back

Cancel

Advanced Operations

Save form for future access, or prepare
a template

[| .HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)

05/22/2018 02:53 PM EDT

ASSIGNMENT

WHEREAS we, the below named inventors (hereinafter referred to as Assignors) have made an invention entitled:

B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

for which we executed United States Provisional Application Nos. 62/550,173 filed on August 25, 2017, 62/579,774 filed on October 31, 2017, 62/607,810 filed on December 19, 2017, and 62/656,789 filed on April 12, 2018; and

WHEREAS, Adimab, LLC, a corporation whose post office address is 7 Lucent Drive, Lebanon NH 03766 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to this provisional patent application and any subsequent application filed in any jurisdiction throughout the world claiming priority to this provisional application, and in and to any Letters Patent to be issued upon this provisional application or on an application claiming priority to this provisional application in any jurisdiction throughout the world;


NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, we, as Assignors, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, and this provisional application, and to all applications in any worldwide jurisdiction that claim priority to this provisional application, including all divisions and continuations thereof, and all Letters Patent in any worldwide jurisdiction that may be granted thereon, including all reissues, reexaminations, renewals, extensions, and supplemental patent certificates thereof. We have also sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns all rights to claim priority in any worldwide jurisdiction on the basis of the above provisional application. We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE HEREBY covenant that we have the full right to convey the interest assigned by this Assignment, and we have not executed and will not execute any agreement in conflict with this Assignment;

AND, WE HEREBY further covenant and agree that we will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country.

AND, WE HEREBY authorize and request the attorneys given power of attorney in this application.

IN TESTIMONY WHEREOF, we have hereunto set our hands.



Nels P. Nielson




DATE

SOLE/JOINT INVENTION
(Worldwide Rights)
Client Reference No. P1052-PR1, PR2, PR3, PR4-US

IN TESTIMONY WHEREOF, ASSIGNEE acknowledges this assignment and hereunto signed ASSIGNEE'S name to this Assignment on the date indicated below.

ADIMAB, LLC.

By: 

Date: MAY 4th 2018

Name: ERIC KRAWLAND

Title: C.S.O.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 23, 2018

PTAS

STERNE, KESSLER, GOLDSTEIN & FOX
P.L.L.C
1100 NEW YORK AVENUE, NW
WASHINGTON, DC 20005

504925698

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 05/22/2018

REEL/FRAME: 045873/0089
NUMBER OF PAGES: 7

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 3986.0090003/EKS/CLD/M-S

ASSIGNOR:
ADIMAB, LLC

DOC DATE: 05/15/2018

ASSIGNEE:
FIVE PRIME THERAPEUTICS, INC.
111 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CALIFORNIA
94080

APPLICATION NUMBER: 62550173

FILING DATE: 08/25/2017

PATENT NUMBER:

ISSUE DATE:

TITLE: B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

APPLICATION NUMBER: 62579774

FILING DATE: 10/31/2017

PATENT NUMBER:

ISSUE DATE:

TITLE: B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

APPLICATION NUMBER: 62607810

FILING DATE: 12/19/2017

PATENT NUMBER:

ISSUE DATE:

TITLE: B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

APPLICATION NUMBER: 62656789

FILING DATE: 04/12/2018

PATENT NUMBER:

ISSUE DATE:

TITLE: B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

ASSIGNMENT RECORDATION BRANCH

PUBLIC RECORDS DIVISION



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)*Electronic Patent Assignment System***Confirmation Receipt**

Your assignment has been received by the USPTO.
The coversheet of the assignment is displayed below:

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1

Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ADIMAB, LLC	05/15/2018
RECEIVING PARTY DATA	
Name:	FIVE PRIME THERAPEUTICS, INC.
Street Address:	111 OYSTER POINT BLVD.
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	62550173
Application Number:	62579774
Application Number:	62607810
Application Number:	62656789

CORRESPONDENCE DATA	
Fax Number:	(202)371-2540
Phone:	2023712600
Email:	msmith@sternekessler.com, deniseb@sternekessler.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C
Address Line 1:	1100 NEW YORK AVENUE, NW
Address Line 4:	WASHINGTON, D.C. 20005
ATTORNEY DOCKET NUMBER:	3986.0090003/EKS/CLD/M-S
NAME OF SUBMITTER:	CYNTHIA L. DERENZO
Signature:	/Cynthia L. DeRenzo #60,789/
Date:	05/22/2018
Total Attachments: 5 source=FPT_ASGN#page1.tif source=FPT_ASGN#page2.tif source=FPT_ASGN#page3.tif source=FPT_ASGN#page4.tif source=FPT_ASGN#page5.tif	
RECEIPT INFORMATION	
EPAS ID:	PAT4972444
Receipt Date:	05/22/2018

[Return to home page](#)

| [.HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)
**Electronic Patent Assignment System**

Patent Assignment Recordation Form

Navigation: [Guidelines](#) - [Conveyance Type](#) - [Correspondence](#) - [Conveyor](#) - [Receiver](#) - [Property](#) -[Attachments](#) - [Sign](#) - [Validate](#)

EPAS v.1.11

PTO-1595 (Rev. 06/12)

OMB No. 0651-0027 (Exp.

04/30/2018)

Validate

All data entered on the previous screens are displayed below. Check the data carefully. If you find any errors, go back to the appropriate screen and correct. Otherwise, select the Submit button to proceed.

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1

Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ADIMAB, LLC	05/15/2018
RECEIVING PARTY DATA	
Name:	FIVE PRIME THERAPEUTICS, INC.
Street Address:	111 OYSTER POINT BLVD.
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	62550173
Application Number:	62579774
Application Number:	62607810
Application Number:	62656789

CORRESPONDENCE DATA	
Fax Number:	(202)371-2540
Phone:	2023712600
Email:	msmith@sternekessler.com, deniseb@sternekessler.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C
Address Line 1:	1100 NEW YORK AVENUE, NW
Address Line 4:	WASHINGTON, D.C. 20005
NAME OF SUBMITTER:	CYNTHIA L. DERENZO
Signature:	/Cynthia L. DeRenzo #60,789/
Date:	05/22/2018
Total Attachments: 5 source=FPT_ASGN#page1.tif source=FPT_ASGN#page2.tif source=FPT_ASGN#page3.tif source=FPT_ASGN#page4.tif source=FPT_ASGN#page5.tif	

Attorney Docket Number:

3986.0090003/EKS/CLD/M-S

This U.S. GOVERNMENT System is for recording documents with the U.S. Patent and Trademark Office.

There is no right to privacy in this system. Use of this system constitutes consent to have activities in association with the submission for recordation monitored, recorded, read, copied or captured by authorized personnel. Unauthorized use of this service, which includes providing false or spurious information such as false or improper assignment documents or security agreements, is a misrepresentation to the federal government. Unauthorized use of this system is prohibited and subject to criminal and civil penalties, including all penalties applicable to willful unauthorized access. See 37 CFR 1.4, 11.18 and 18 U.S.C. 1001.

The USPTO reserves the right, at its complete discretion, to change the terms, conditions, and use at any time by posting revised terms, conditions, and use restrictions for this system. It is the user's responsibility to check periodically for any changes USPTO may make to these terms, conditions, and use restrictions. Continued use of this system following the posting of changes to these terms, conditions, and use restrictions means you accept the changes.

☒ **By checking this box, you acknowledge your consent to the above statement.**

Your IP address: 208.184.134.166

Submit

Back

Cancel

Advanced Operations

Save form for future access, or prepare
a template

| [.HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)

05/22/2018 02:54 PM EDT

ASSIGNMENT

For good and sufficient consideration, receipt of which is hereby acknowledged, Adimab, LLC, a corporation organized and existing under the laws of Delaware and having an office and place of business at 7 Lucent Drive, Lebanon NH 03766 (hereafter referred to as the "Assignor"), hereby sells and assigns to Five Prime Therapeutics, Inc., a corporation formed under the laws of Delaware, having an office and place of business at 111 Oyster Point Blvd, South San Francisco, CA 94080 (hereafter referred to as the "Assignee"), its entire right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), and throughout the world, including the right to sue for past infringement and to collect for all past, present and future damages,

(a) in each of the Patents and Patent Applications that are set forth in Schedule A, annexed hereto and made a part hereof;

(b) in any and all applications that claim the benefit of the Patents and Patent Applications set forth in Schedule A, including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals, and reexaminations of such Patents and Patent Applications, to the full extent of the term or terms for which Letters Patents issue; and

(c) in any and all inventions described in each of the Patents and Patent Applications set forth in Schedule A, and in all forms of intellectual and industrial property protection derivable therefrom, and that are derivable from any and all non-provisional applications, continuing applications, reissues, extensions, renewals and reexaminations of such Patents and Patent Applications, including, without limitation, patents, applications, utility models, inventor's certificates, and designs, together with the right to file applications therefor; and

(d) in any and all applications for patent of the United States or any other country claiming any invention described in each of the Patents and Patent Applications set forth in Schedule A, together with the right to file applications therefor, including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable, and all rights of claiming priority to such Patents and Patent Applications in connection therewith; and

(e) any patents of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (a)-(d), including any reissues, extensions, renewals and reexaminations of said patents;

and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee, then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold and assigned, and by these legal presents does sell and assign, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title and interest as set forth above;

and all such right, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The Assignor agrees to execute all papers and do all acts necessary in connection with the procurement and maintenance of said applications and Letters Patents as above, and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding applications thereof, and also to execute separate assignments in connection with such applications and Letters Patent as the Assignee may deem necessary or expedient.


The Assignor agrees to execute all papers and do all acts necessary in connection with any patent enforcement or defense proceeding (judicial, administrative or otherwise), including but not limited to interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *inter partes* reviews, and supplemental examinations) related to the applications or Letters Patents or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application thereof and to cooperate with the Assignee at Assignee's expense in every reasonable way possible in obtaining evidence and going forward with such patent enforcement or defense proceeding.

The Assignor agrees to perform all affirmative acts at Assignee's request and expense that may be necessary to obtain or ensure a grant of a valid patent to the Assignee.

The Assignor hereby represents that Assignor has full right and authority to convey the entire interest herein assigned, and that Assignor has not executed, and will not execute, any agreement in conflict therewith.

The Assignor hereby grants the patent practitioners associated with **CUSTOMER NUMBER 147646** the power to insert in this assignment, including the attached Schedule A, any further information regarding the patents and patent applications so identified in such Schedule A that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

SIGNED on behalf of the said ASSIGNOR,

By: 
Name: Ryan McKeown
Title: SVP Finance
Date: 5/15/18

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of New Hampshire

County of Grafton

On May 15, 2018 before me, Laura C. Pierce, personally appeared

Ryan McGovern, who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature Laura C. Pierce

Place Notary Seal above

LAURA CAITLIN PIERCE, Notary Public
State of New Hampshire
My Commission Expires September 13, 2022

IN TESTIMONY WHEREOF, ASSIGNEE acknowledges this assignment and hereunto signed ASSIGNEE'S name to this Assignment on the date indicated below.

FIVE PRIME THERAPEUTICS, INC.

By: [Signature]

Date: May 21, 2018

Name: Francis Sarena

Title: Chief Strategy Officer and Secretary

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT


A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California

County of San Mateo

On May 21, 2018 before me, Teri Lee, Notary Public, personally appeared

Francis Sarena, who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/~~she~~/they executed the same in his/~~her~~/their authorized capacity(ies), and that by his/~~her~~/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.



Place Notary Seal above

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal

Signature [Signature]

FivePrime Reference No's: P1052-PR1, PR2, PR3, PR4-US

SCHEDULE A

**UNITED STATES PATENTS, UNITED STATES PATENT APPLICATIONS AND
INTERNATIONAL APPLICATIONS THAT DESIGNATE THE UNITED STATES**

Five Prime Reference	Application No.	Filing Date	Status
P1052-PR1-US	62/550,173	August 25, 2017	Pending
P1052-PR2-US	62/579,774	October 31, 2017	Pending
P1052-PR3-US	62/607,810	December 19, 2017	Pending
P1052-PR4-US	62/656,789	April 12, 2018	Pending



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

SEPTEMBER 25, 2018

PTAS

STERNE, KESSLER, GOLDSTEIN & FOX
P.L.L.C.
1100 NEW YORK AVENUE, NW
WASHINGTON, DC 20005

505108519

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 09/24/2018

REEL/FRAME: 046952/0634
NUMBER OF PAGES: 2

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 3986.009PC04/EKS/CLD/M-S

ASSIGNOR:
SCHMIDT, MAIKE

DOC DATE: 08/08/2018

ASSIGNEE:
FIVE PRIME THERAPEUTICS, INC.
111 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CALIFORNIA
94080

APPLICATION NUMBER:
PATENT NUMBER:
PCT NUMBER: US2018047805
TITLE: B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

FILING DATE: 08/23/2018
ISSUE DATE:

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

SOLE/JOINT INVENTION
(Worldwide Rights)
Client Reference No. P1052-WO

ASSIGNMENT

WHEREAS I/we, the below named inventor(s) (hereinafter referred to as Assignor(s)) have made an invention entitled: **B7-H4 ANTIBODIES AND METHODS OF USE THEREOF** for which I/we executed PCT Application Nos. PCT/US18/47805 * filed on Aug. 23, 2018 *; and

36,688

WHEREAS, Five Prime Therapeutics, Inc., a corporation whose post office address is 111 Oyster Point Blvd, South San Francisco, California 94080 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to this patent application and any subsequent application filed in any jurisdiction throughout the world claiming priority to this application, and in and to any Letters Patent to be issued upon this application or on an application claiming priority to this application in any jurisdiction throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I/we, as Assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, and this application, and to all applications in any worldwide jurisdiction that claim priority to this application, including all divisions and continuations thereof, and all Letters Patent in any worldwide jurisdiction that may be granted thereon, including all reissues, reexaminations, renewals, extensions, and supplemental patent certificates thereof. I/we have also sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns all rights to claim priority in any worldwide jurisdiction on the basis of the above application. I/we hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY covenant that I/we have the full right to convey the interest assigned by this Assignment, and we have not executed and will not execute any agreement in conflict with this Assignment;

AND, I/WE HEREBY further covenant and agree that I/we will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country.

AND, I/WE HEREBY authorize and request the attorneys given power of attorney in this application.


IN TESTIMONY WHEREOF, I/we have hereunto set our hands.

DocuSigned by:

Maile Schmidt
August 8, 2018
Date

IN TESTIMONY WHEREOF, ASSIGNEE acknowledges this assignment and hereunto signed ASSIGNEE'S name to this Assignment on the date indicated below.

FIVE PRIME THERAPEUTICS, INC.

By: 
Name: Francis Sarena
Title: Chief Strategy Officer and Secretary

Date: 13 Aug 2018

*Application number and filing date will be added to the document once available.